European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 123, Issue 2, 1 December 2005, Pages 260-262
LETTER TO THE EDITOR—BRIEF COMMUNICATIONChemotherapy for breast cancer during pregnancy
Section snippets
Acknowledgements
The authors thank R. Renaud, J.P. Brettes, J.P. Bellocq, M.P. Chenard, C. Tomasetto, P. Quetin, N. Arnould and D. Annane who have participated in this study.
References (5)
- et al.
Use of chemotherapy during human pregnancy
Lancet Oncol
(2004) - et al.
Chemotherapy during pregnancy: what is really safe?
Lancet Oncol
(2004)
There are more references available in the full text version of this article.
Cited by (11)
Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy
2018, Seminars in OncologyBreast cancer during pregnancy and chemotherapy: A systematic review
2013, Revista da Associacao Medica BrasileiraTreatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors
2010, Cancer Treatment ReviewsCitation Excerpt :Pregnancy course and outcomes were normal, with the exception of one case of eclampsia after two cycles of FEC.20 Both doxorubicin15,17,22 and epirubicin23 were used either as single agents or in combination with 5-fluorouracil24 with normal outcomes. Recently, the incorporation of taxanes has been shown to improve outcomes in the adjuvant and neoadjuvant settings.25
Chemotherapy for breast cancer during pregnancy: Is epirubicin safe?
2008, Annals of OncologyBreast cancer and pregnancy
2005, Obstetrics and Gynecology Clinics of North AmericaPrimary Ewing's Sarcoma/Primitive Neuroectodermal Tumor of Kidney with Caval Involvement in a Pregnant Woman
2016, Urologia Internationalis
Copyright © 2005 Elsevier Ireland Ltd. All rights reserved.